Study guide

4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

Key Takeaways Explain This Topic AI

Infertility is clinically defined as the failure to achieve clinical pregnancy after 12 months of regular, unprotected sexual intercourse in women under age 35, or after 6 months in women aged 35 years and older; immediate evaluation is warranted for patients aged >=40, or with oligomenorrhea, known endometriosis, or pelvic inflammatory disease.

The initial diagnostic evaluation addresses the essential triad: male factor assessment via semen analysis, ovulatory confirmation via mid-luteal serum progesterone (>3 ng/mL confirms ovulation), and anatomical assessment of tubal patency and uterine contour via hysterosalpingography (HSG) performed during cycle days 7–10.

Semen analysis interpretation follows the WHO 6th edition lower reference limits: volume >=1.4 mL, sperm concentration >=16 million/mL, total motility >=42%, progressive motility >=30%, and strict Kruger normal morphology >=4%.

Ovarian reserve testing integrates cycle-independent anti-Müllerian hormone (AMH; <1.0 ng/mL indicates diminished reserve), early follicular antral follicle count (AFC; <5–7 indicates diminished reserve), and cycle day 3 FSH and estradiol.

First-line ovulation induction for anovulatory PCOS is the aromatase inhibitor letrozole (superior live-birth and lower multiple gestation rates compared to clomiphene citrate); assisted reproductive technologies (IUI, IVF, ICSI, PGT) address refractory and structural etiologies, requiring vigilant monitoring for ovarian hyperstimulation syndrome (OHSS).

Last updated: October 2026

Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

Infertility affects approximately 1 in 6 couples globally. Modern clinical practice emphasizes an evidence-based, rapid diagnostic workup that evaluates male, ovulatory, and anatomical factors concurrently before initiating targeted medical, surgical, or assisted reproductive interventions.

Important

Both partners must be evaluated concurrently from the onset. Because male factor subfertility contributes to 40% to 50% of cases, a non-invasive semen analysis is mandatory at the initial visit before embarking on invasive female procedures.

Clinical Definitions & Evaluation Timelines

The American Society for Reproductive Medicine (ASRM) and ACOG establish age-stratified thresholds reflecting the natural decline in female fecundability (monthly probability of conceiving):

Women Under 35 Years: Evaluation begins after 12 months of regular, unprotected intercourse without conception (normal fecundability is 20%–25% per cycle; ~85% conceive within 12 months).

Women Aged 35 to 39 Years: Evaluation begins after 6 months of unprotected intercourse, reflecting accelerated oocyte atresia and declining oocyte quality.

Women Aged 40 Years and Older: Immediate evaluation and specialist referral upon presentation, as fecundability drops to <5% per cycle with high miscarriage risk.

Immediate Evaluation at Any Age:

Oligomenorrhea or amenorrhea.

Known/suspected uterine, tubal, or pelvic peritoneal disease (history of stage III–IV endometriosis, prior pelvic inflammatory disease [PID], ectopic pregnancy, pelvic tuberculosis, ruptured appendicitis).

Prior pelvic radiation, gonadotoxic chemotherapy, or ovarian surgery.

Known subfertile male partner (cryptorchidism, mumps orchitis, varicocele).

Etiologic Distribution

Male factor accounts for 35%–40% (sole cause in 20%–30%; contributory in 10%–20%); Ovulatory dysfunction 25%–30%; Tubal/pelvic pathology 20%–25%; Uterine/cervical factors 3%–5%; and Unexplained infertility 15%–20%.

The Essential Diagnostic Triad

A comprehensive evaluation simultaneously assesses the sperm, the egg, and the transport conduit.

1. Male Factor Assessment: Semen Analysis

Specimen is collected by masturbation after 2 to 7 days of sexual abstinence and analyzed within 60 minutes.

If abnormal, perform a confirmatory repeat analysis 2 to 4 weeks later (spermatogenesis takes ~74 days; transient illness or heat exposure can temporarily impair parameters).

  • Semen Parameter WHO 6th Edition Lower Reference Limit (5th Percentile) Classification if Subnormal
  • Semen Volume >= 1.4 mL Hypospermia (<1.4 mL) or Aspermia (0 mL)
  • Total Sperm Count >= 39 million per ejaculate Oligozoospermia (<39 million/ejaculate)
  • Sperm Concentration >= 16 million/mL Oligozoospermia (<16 million/mL)
  • Total Motility (PR + NP) >= 42% Asthenozoospermia (<42% total motility)
  • Progressive Motility (PR) >= 30% Asthenozoospermia (<30% progressive)
  • Vitality (Live Sperm) >= 54% Necrozoospermia (<54% viable)
  • Morphology (Kruger Strict) >= 4.0% normal forms Teratozoospermia (<4.0% normal forms)
  • Leukocyte Concentration < 1.0 million/mL Leukocytospermia (>=1.0 M/mL, suggests infection)

Note

Complete absence of sperm is azoospermia . Differentiate obstructive azoospermia (normal testicular size, normal FSH; e.g., congenital bilateral absence of vas deferens [CBAVD, test CFTR gene]) from non-obstructive azoospermia (testicular failure, elevated FSH; e.g., Klinefelter syndrome 47,XXY, Y-chromosome microdeletions).

2. Ovulatory Factor Assessment

Mid-Luteal Phase Serum Progesterone: Drawn 7 days prior to expected menses (Day 21 of a 28-day cycle, or Day 28 of a 35-day cycle). A value >3 ng/mL confirms recent ovulation and corpus luteum formation; >10 ng/mL demonstrates robust luteal progesterone production in an unmedicated cycle.

Urinary LH Detection Kits: Detects the urinary LH surge preceding ovulation by 24 to 36 hours.

Basal Body Temperature (BBT): Progesterone-induced biphasic shift (0.4°F–0.8°F / 0.2°C–0.4°C rise) confirms ovulation retrospectively.

3. Anatomical & Tubal Patency Assessment

Hysterosalpingography (HSG): Fluoroscopic exam with cervical instillation of radiopaque iodinated contrast to visualize the uterine cavity contour and tubal patency.

Timing: Scheduled strictly in the early follicular phase (cycle days 7 to 10) , after menstrual bleeding ceases but prior to ovulation. This ensures a thin endometrium for visualization, avoids disrupting an unrecognized luteal pregnancy, and lowers infection risk.

Findings: Free peritoneal spill confirms patency. Identifies proximal occlusion or distal hydrosalpinx. Oil-soluble contrast medium (OSCM) provides therapeutic benefit by dislodging intratubal mucous plugs.

Saline Infusion Sonohysterography (SIS): Superior to HSG for intracavitary pathology (submucosal fibroids, polyps, synechiae).

Laparoscopy with Chromopertubation: Gold standard for direct peritoneal visualization, adhesiolysis, and endometriosis resection.

Ovarian Reserve Testing (ORT)

ORT evaluates follicular pool quantity , not oocyte genetic quality (which is dictated by maternal age).

Anti-Müllerian Hormone (AMH):

Secreted by granulosa cells of preantral and small antral follicles (2–8 mm).

Cycle-Independent: Can be drawn on any day of the menstrual cycle .

Normal: 1.0 to 3.5 ng/mL. <1.0 ng/mL indicates Diminished Ovarian Reserve (DOR) (<0.5 ng/mL reflects severe depletion). >3.5 to 4.0 ng/mL suggests PCOS and flags elevated risk for Ovarian Hyperstimulation Syndrome (OHSS).

Antral Follicle Count (AFC): Early follicular transvaginal ultrasound summing all 2–10 mm follicles. An AFC <5 to 7 total follicles indicates DOR; >20 indicates polycystic morphology.

Day 3 Serum FSH & Estradiol: Drawn cycle day 2–4. As ovarian reserve shrinks, declining inhibin B causes day 3 FSH to rise (>10 to 12 IU/L) . An elevated day 3 estradiol (>60–80 pg/mL) from premature follicular recruitment artificially suppresses FSH into the normal range (false-negative FSH).

Ovulation Induction Pharmacotherapy

Letrozole (Femara) — First-Line for PCOS:

Mechanism: Non-steroidal aromatase inhibitor that selectively blocks CYP19A1, suppressing estrogen synthesis. Decreased negative feedback increases pituitary FSH release, driving monofollicular growth.

Dosing: 2.5 to 7.5 mg daily for 5 days starting on cycle day 3, 4, or 5 .

Clinical Advantage: Established as the first-line agent for anovulatory PCOS by the PPCOS II trial (higher live-birth rates [27.5% vs 19.1%], higher ovulation rates, faster conception, and lower multiple pregnancy rates than clomiphene). Does not deplete peripheral estrogen receptors, preserving endometrial thickness (>=8 mm) and cervical mucus.

Clomiphene Citrate (Clomid): Selective Estrogen Receptor Modulator (SERM) that depletes hypothalamic estrogen receptors, stimulating GnRH and FSH/LH pulses. Dosed 50 to 150 mg daily for 5 days starting cycle day 3 or 5. Adverse effects include hot flashes, mood lability, visual scotomas (mandates stopping), and anti-estrogenic endometrial thinning (<7 mm) in up to 30% of cycles.

Exogenous Gonadotropins: Injectable rFSH or hMG for oral agent failure or IVF. Carries high risk of multifollicular development, high-order multiple gestations, and OHSS; requires close ultrasound and estradiol monitoring.

Assisted Reproductive Technologies (ART) & Complications

Intrauterine Insemination (IUI): Washed, concentrated motile sperm placed into the uterine fundus via catheter at ovulation (triggered by hCG 36 hours prior). Used for mild male subfertility, cervical factor, donor sperm, and unexplained infertility. Requires at least one patent tube and adequate motile sperm (>5–10 million).

In Vitro Fertilization (IVF): Controlled ovarian hyperstimulation, ultrasound-guided transvaginal oocyte retrieval under sedation, laboratory fertilization, blastocyst culture (day 5), and embryo transfer. Indicated for tubal obstruction, severe male factor, diminished reserve, advanced maternal age, and failed IUI.

Intracytoplasmic Sperm Injection (ICSI): Direct microinjection of a single sperm into a mature metaphase II oocyte. Standard for severe male factor infertility (severe oligoasthenoteratozoospermia, surgically retrieved sperm via TESE).

Preimplantation Genetic Testing (PGT): Biopsy of day-5 blastocysts for aneuploidy (PGT-A), monogenic single-gene disorders (PGT-M), or structural rearrangements (PGT-SR).

Complications:

Ovarian Hyperstimulation Syndrome (OHSS): Triggered by hCG; massive ovarian VEGF secretion causes widespread capillary hyperpermeability. Intravascular fluid shifts into third spaces, causing ascites, pleural effusions, hemoconcentration (hematocrit >45%–55%), oliguria, and thromboembolism. Prevented by GnRH agonist trigger , cabergoline, and "freeze-all" strategies.

Multiple Gestations: Elective Single Embryo Transfer (eSET) at the blastocyst stage is the standard of care to achieve singleton pregnancies and avoid prematurity risks.